Novavax reported $-476240000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Agenus AGEN:US USD -39945000 3.34M
AstraZeneca AZN:LN USD 3.6B 404M
Astrazeneca AZN:US USD 3.6B 404M
Genocea Biosciences GNCA:US USD -15373000 2.37M
GlaxoSmithKline GSK:LN GBP 3.36B 916M
Mannkind MNKD:US USD -9640000 13.91M
Minerva Neurosciences NERV:US USD -5205000 1.76M
Moderna Inc MRNA:US USD 1.28B 1.24B
Novartis NVS:US USD 4.69B 34M
Pain Therapeutics PTIE:US USD -21045000 1.43M
Peregrine Pharmaceuticals PPHM:US USD 4.34M 1.85M
Pfizer PFE:US USD 10.52B 2.78B
Sarepta Therapeutics SRPT:US USD -120652000 80.59M
Tg Therapeutics TGTX:US USD -34887000 3.98M